Neurometrix (NASDAQ:NURO) announced its quarterly earnings data on Thursday. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.02, Morningstar.com reports. Neurometrix had a return on equity of 11.77% and a net margin of 6.36%. The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $3.28 million.
NASDAQ NURO traded up $0.01 during trading on Friday, hitting $0.39. 118 shares of the company traded hands, compared to its average volume of 134,177. Neurometrix has a 12 month low of $0.35 and a 12 month high of $1.40. The business’s fifty day simple moving average is $0.50. The company has a market cap of $3.39 million, a P/E ratio of 3.27 and a beta of 0.50.
Several equities analysts have weighed in on NURO shares. HC Wainwright restated a “buy” rating on shares of Oragenics in a report on Friday, April 26th. Zacks Investment Research lowered GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. Finally, ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd.
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.
Recommended Story: How does a security become overbought?
Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.